Results 201 to 210 of about 605,029 (256)

Dual Receptor Targeting Ensures Uptake and Anticancer Efficacy of Low-Density Lipoprotein-Docosahexaenoic Acid Nanoparticles Across Breast Cancer Cell Subtypes. [PDF]

Breast Cancer (Dove Med Press)
Bower J, Anwar A, Chaudhary J, Chen Z, Schumacher M, Debose-Boyd R, Corbin IR.   +6 more
europepmc   +1 more source

Metabolic Dysfunction-Associated Steatotic Liver Disease: From a Very Low-Density Lipoprotein Perspective. [PDF]

Biomolecules
Chen Y, Lei K, Liu Y, Liu J, Wei K, Guo J, Su Z.   +6 more
europepmc   +1 more source

Correction for Jang et al., Lipid raft proteomics identify endothelial myosin-9 (MYH9) as a regulator of low-density lipoprotein transcytosis and atherosclerosis. [PDF]

Proc Natl Acad Sci U S A
europepmc   +1 more source

Low-Density Lipoprotein Cholesterol Levels and Bleeding Risk in Venous Thromboembolism.

JAMA Netw Open
Siniscalchi C, Meschi T, Di Micco P, Imbalzano E, Hernández-Blasco L, Mahé I, Fernández-Reyes JL, García-Ortega A, Verhamme P, Alfonso-Megido J, Monreal M, RIETE Investigators.   +11 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Electronegative low-density lipoprotein

Current Opinion in Lipidology, 2004
The occurrence in blood of an electronegatively charged LDL was described in 1988. During the 1990s reports studying electronegative LDL (LDL(-)) were scant and its atherogenic role controversial. Nevertheless, recent reports have provided new evidence on a putative atherogenic role of LDL(-).
José Luis, Sánchez-Quesada, Sonia, Benítez, Jordi, Ordóñez-Llanos   +2 more
openaire   +2 more sources

Low-density lipoprotein heterogeneity

Baillière's Clinical Endocrinology and Metabolism, 1995
As a key feature of the ALP, a raised level of small, dense LDL forms part of what is potentially the most common collection of lipoprotein abnormalities to influence the risk of CHD in the general population. The consistency of the association between a prevalence of small, dense LDL and increased risk of CHD is impressive, though the practical ...
openaire   +2 more sources

Circulating low density lipoprotein (LDL)

Hormone Molecular Biology and Clinical Investigation, 2018
Abstract Low-density lipoprotein (LDL) particles are known as atherogenic agents in coronary artery diseases. They modify to other electronegative forms and may be the subject for improvement of inflammatory events in vessel subendothelial spaces. The circulating LDL value is associated with the plasma PCSK-9 level. They internalize into
Mohsen, Khosravi, Reza, Hosseini-Fard, Mohammad, Najafi   +2 more
openaire   +2 more sources

Evaluation of Malondialdehyde Low-Density Lipoprotein Stratified by Low-Density Lipoprotein Cholesterol

Clinical Laboratory, 2017
Malondialdehyde low-density lipoprotein (MDA-LDL) is a major form of oxidized LDL and considered to be more atherogenic than LDL. Information on major determinants of MDA-LDL and their association in subjects who are not under treatment for diabetes mellitus and dyslipidemia is limited.This study included 778 Japanese subjects who were not taking ...
Kengo, Moriyama, Eiko, Takahashi
openaire   +2 more sources

Modified Low-Density Lipoproteins and High-Density Lipoproteins

Pathophysiology of Haemostasis and Thrombosis, 2006
It has long been known that the oxidative state of the various plasma lipoproteins modulates platelet aggregability, thereby contributing to atherogenesis. Low-density lipoprotein (LDL), occurring in vivo both in the native and oxidised forms, interacts directly with platelets, by binding to specific receptors.
Elisabeth Koller, Ivo Volf, Aner Gurvitz, Franz Koller   +3 more
openaire   +1 more source